Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey-Reference-Cited by-同舟云学术

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey

Published:2019-01-29 Issue:5 Volume:98 Page:1119-1125
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Yu Jingbo,Paranagama Dilan,Geyer Holly L.,Parasuraman Shreekant,Mesa Ruben

Funder

Incyte Corporation

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-019-03610-4/fulltext.html

Reference20 articles.

1. Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9(3):e90299

2. Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bjorkholm M (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30(24):2995–3001. https://doi.org/10.1200/JCO.2012.42.1925

3. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAW, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form Total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103. https://doi.org/10.1200/JCO.2012.42.3863

4. Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer 16:167. https://doi.org/10.1186/s12885-016-2208-2

5. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA (2011) The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2):401–408. https://doi.org/10.1182/blood-2011-01-328955

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct and indirect costs for patients with myeloproliferative neoplasms;Leukemia & Lymphoma;2024-04-27

2. Extending the job demands–resources model to understand the effect of the interactions between home and work domains on work engagement;Stress and Health;2024-01-10

3. Quality of life and affecting factors in myelofibrosis patients;2023-08-31

4. Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder;Frontiers in Oncology;2023-06-09

5. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study;Therapeutic Advances in Hematology;2022-01